What is Driving the Global Gastric Cancer Market Growth?
The global gastric cancer market was valued at USD 4.70 billion in 2024 and is projected to reach USD 15.44 billion by 2034, growing at a CAGR of 12.63%. The rising incidence of gastric cancer, increasing awareness about early diagnosis, and advances in targeted drug therapies are fueling this market’s expansion.
Globally, gastric cancer remains one of the leading causes of cancer-related deaths. The growing investment in oncology research, expansion of clinical trials, and introduction of personalized immunotherapies are transforming treatment approaches. Moreover, the increasing availability of innovative drugs and supportive government initiatives are significantly improving patient outcomes.
Key Highlights of the Gastric Cancer Market
-
Market Size (2024): USD 4.70 Billion
-
Forecast Value (2034): USD 15.44 Billion
-
CAGR (2025–2034): 12.63%
-
Growth Drivers: Rising incidence of gastric cancer, immunotherapy advancements, and expanding oncology research
-
Key Players: AstraZeneca, Pfizer, Novartis, Amgen, Bristol Myers Squibb, Eli Lilly, AbbVie, and others
Gastric Cancer Market Trends and Growth Drivers
1. Increasing Prevalence and Awareness
The growing global burden of gastric cancer, particularly in Asia-Pacific and Europe, is driving market demand for better diagnostic and treatment options. Rising healthcare awareness and national cancer control programs are helping to promote early detection and screening.
-
Increasing cases in Japan, China, and South Korea are contributing significantly to market growth.
-
Governments are funding cancer registries and early intervention programs to reduce mortality rates.
2. Advancements in Targeted and Immunotherapies
Targeted therapies and immune checkpoint inhibitors such as pembrolizumab and nivolumab have shown promising results in managing advanced gastric cancer. Pharmaceutical companies are investing heavily in clinical research to develop new molecules and combination therapies.
-
Personalized medicine approaches are becoming mainstream in oncology.
-
Biotech firms are focusing on PD-1/PD-L1 inhibitors for better outcomes in gastric cancer patients.
3. Rising Clinical Trials and R&D Investments
The surge in clinical trials targeting novel treatment mechanisms is expanding the therapeutic landscape. Companies like AstraZeneca, Pfizer, and Amgen are leading innovation through drug discovery programs and collaborative oncology research.
-
Increase in phase III clinical trials for advanced-stage patients.
-
Partnerships between academic research institutions and pharma companies are driving new drug approvals.
4. Expanding Healthcare Infrastructure and Accessibility
Improved healthcare infrastructure and better access to cancer care facilities in developing countries are strengthening market growth. Moreover, expanding reimbursement coverage for cancer treatments encourages patients to opt for advanced therapies.
Market Segmentation Analysis
By Treatment Type
-
Chemotherapy: Continues to be the cornerstone of gastric cancer treatment, especially for advanced stages.
-
Immunotherapy: Expected to grow rapidly due to success with checkpoint inhibitors and personalized medicine.
-
Surgery: Essential for early-stage gastric cancer; advancements in minimally invasive techniques are improving recovery rates.
-
Targeted Drug Therapy: Represents one of the fastest-growing segments due to precision medicine approaches.
-
Others: Includes palliative care and radiation therapy.
By Cancer Type
-
Adenocarcinoma: Accounts for the largest market share as it represents nearly 90% of gastric cancer cases.
-
Gastrointestinal Stromal Tumor (GIST): Driven by the adoption of targeted drugs like imatinib.
-
Carcinoid Tumor: A smaller but emerging segment due to improved detection methods.
-
Others: Includes rare malignancies and mixed tumor types.
By Route of Administration
-
Oral: Preferred for targeted drugs and convenience in outpatient settings.
-
Parenteral: Common for chemotherapy and biologics administered intravenously.
-
Others: Includes localized delivery methods in clinical research.
By End User
-
Hospitals & Clinics: Dominate due to comprehensive cancer care facilities and access to oncology specialists.
-
Diagnostic Centers: Growing in importance for early screening and staging.
-
Research Laboratories: Driving the development of new treatment modalities and biomarker studies.
-
Others: Includes ambulatory centers and specialty cancer institutes.
Regional Analysis of the Gastric Cancer Market
North America
North America represents a major share due to advanced healthcare systems, growing adoption of targeted therapies, and strong pharmaceutical R&D activities. The U.S. leads the market with the presence of top oncology drug manufacturers and ongoing clinical trials.
Europe (EU-4 and the United Kingdom)
Europe holds a significant portion of the market due to robust clinical trial networks and government-funded cancer programs. Germany, France, and the U.K. are at the forefront of biopharmaceutical innovation.
Asia Pacific
Asia Pacific is the fastest-growing region, driven by high gastric cancer prevalence in Japan, China, and South Korea. Strong government health initiatives and increasing adoption of innovative therapies are propelling regional market growth.
Latin America
Countries such as Brazil and Mexico are witnessing improved access to cancer diagnosis and treatment. Growing healthcare expenditure supports the market’s steady expansion.
Middle East and Africa
The region shows gradual growth due to rising investments in healthcare infrastructure and medical tourism, particularly in the Gulf Cooperation Council (GCC) countries.
Competitive Landscape
The gastric cancer treatment market is characterized by rapid innovation, extensive research collaborations, and strong competition among key pharmaceutical companies.
Leading Companies Include:
-
AstraZeneca
-
Pfizer, Inc.
-
Novartis AG
-
Amgen Inc.
-
Bristol Myers Squibb Company
-
Eli Lilly and Company
-
Celltrion
-
AbbVie Inc.
-
GSK plc
Key Strategic Initiatives:
-
AstraZeneca focuses on immuno-oncology therapies through its PD-1 inhibitor pipeline.
-
Pfizer and Amgen are investing in combination regimens that improve patient survival.
-
Novartis emphasizes biologics and targeted therapy for HER2-positive gastric cancer.
-
Collaborations between pharmaceutical giants and research institutes are accelerating drug approvals and biomarker-based treatments.
Future Outlook of the Gastric Cancer Market
The future of the gastric cancer market looks promising as the industry moves toward precision medicine, early detection technologies, and combination therapies. The integration of AI-based diagnostics and genomic profiling is expected to further enhance treatment accuracy.
Expected Developments by 2034:
-
Rise in personalized immunotherapy and genetic-based treatments.
-
Digital health integration for real-time monitoring and follow-up.
-
Expansion in emerging markets through government support and international collaborations.
As the prevalence of gastric cancer rises and healthcare systems strengthen, the market is set to see transformative growth across all major regions.
Key Takeaways
-
The gastric cancer market will reach USD 15.44 billion by 2034, growing at a CAGR of 12.63%.
-
Rising R&D investments and clinical trials are key growth drivers.
-
Immunotherapy and targeted therapy are revolutionizing treatment approaches.
-
Asia Pacific is projected to be the fastest-growing region.
See More Reports
About Us:
Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others.
Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.
Media Contact:
Company Name: Claight Corporation
Contact Person: Roshan Kumar, Digital Marketing
Email: sales@expertmarketresearch.com
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com